According to an announcement made by the company on 5th October, Animas Corporation is to close operations and exit the insulin pump market in the US and Canada immediately. The company is to work with Medtronic as a partner-of-choice to help ensure a smooth transition for patients on insulin pumps to Medtronic’s products.
The company will be existing the insulin pump market globally – including the UK – at a future date, yet to be specified. Existing users will be contacted directly in due course, likely within the next few months*.
According to a report on Medtronic’s US website, “Animas will close its pump business. As Animas’ partner-of-choice for this transition, our Medtronic team is ready to help. We know that when it comes to your diabetes management needs, it’s a very personal decision and our experienced team is here to support you through every step in the process.”
Animas’s announcement further states, “Animas has discontinued the sale of all Animas Vibe and OneTouch Ping insulin pumps in the US and Canada, effective immediately. A decision and timing to exit countries outside of the US and Canada is subject to completing consultation with relevant works councils. For the patients, caregivers and healthcare providers outside of the US and Canada who currently use Animas pumps and products, Animas will continue to sell pumps and operate as usual.”
As part of the strategic review process for the Johnson & Johnson Diabetes Care Companies announced in January 2017, Johnson & Johnson is also continuing to evaluate potential strategic options for LifeScan, Inc., a world leader in blood glucose monitoring with the OneTouch brand of products, and also the Calibra brand of insulin delivery devices.
*Due to the consultative nature of the global withdrawal of Animas from the insulin pump arena, it is not possible to be specific about a date on this. However, we (Desang Media) will report again as soon as anything further is known.
To reiterate, for the people with diabetes, caregivers and healthcare providers in Europe, the Middle East and Africa (EMEA), who currently use Animas pumps and products, Animas will continue to sell pumps and operate as usual.
EMEA (Europe, Middle East and Africa) decision, timing to exit and impact on Johnson & Johnson Diabetes Care Companies roles is subject to completion of our consultation process which may include works councils in some countries.
Animas will continue to deliver customer service, training and warranty support, including providing pump supplies that are used in conjunction with the Animas Vibe, through a transition period which is being defined now.
We (Johnson & Johnson Diabetes Care Companies) will come back to you with more news as soon as we can.
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes kit) and news about food suitable for a diabetic diet. Go to the top of this page to sign up – we just need your email address. www.desang-magazine.co.uk